Weight Loss Effectiveness
Ozempic (semaglutide) and Mounjaro (tirzepatide) both drive weight loss by mimicking gut hormones that reduce appetite and slow digestion, but Mounjaro shows stronger results in head-to-head trials. In the SURMOUNT-5 trial, Mounjaro users lost 20.2% of body weight on average after 72 weeks, compared to 13.7% for Ozempic users at similar doses.[1] Real-world data aligns: Mounjaro patients often drop 15-25% of weight over a year, while Ozempic averages 10-15%.[2]
How They Work and Key Differences
Ozempic targets GLP-1 receptors only. Mounjaro activates both GLP-1 and GIP receptors, potentially boosting fat metabolism and insulin response more effectively—this dual action explains its edge in trials.[3] Both are weekly injections; Mounjaro comes in higher-dose pens (up to 15mg), while Ozempic maxes at 2mg for diabetes (higher Wegovy doses exist for weight loss but aren't Ozempic).
| Aspect | Ozempic | Mounjaro |
|--------|---------|----------|
| Active Ingredient | Semaglutide | Tirzepatide |
| Receptor Targets | GLP-1 only | GLP-1 + GIP |
| FDA Approval | Diabetes (weight loss off-label or via Wegovy) | Diabetes + chronic weight management |
| Max Weekly Dose | 2mg | 15mg |
| Avg. Weight Loss (1 year) | 12-15% | 18-22%[4] |
Side Effects and Tolerability
Both cause nausea, vomiting, diarrhea, and constipation—most common early on and fading over time. Mounjaro has slightly higher GI issues at start but better long-term tolerance in some studies; Ozempic reports more gallbladder problems.[5] Rare risks like pancreatitis or thyroid tumors apply to both. Patients switch to Mounjaro for faster loss despite similar profiles.
Cost and Access
Without insurance, Ozempic runs $900-1,300/month; Mounjaro $1,000-1,300. Copays drop to $25-100 with coverage, but shortages hit both—Ozempic eases, Mounjaro persists.[6] Compounded versions (semaglutide/tirzepatide) cost $200-500/month but carry FDA warnings on safety.
Who Gets Better Results?
Mounjaro outperforms for most, especially higher BMI patients or stalled Ozempic users. Men and those with insulin resistance see bigger gains on Mounjaro. Start Ozempic if cost or availability favors it; switch if plateauing.[7] Doctors monitor heart benefits—both cut CV risk, Mounjaro slightly more in diabetes trials.
Alternatives if Neither Fits
Wegovy (higher-dose semaglutide) matches Mounjaro's loss at 15-20%. Zepbound (Mounjaro's weight-loss twin) is identical. Oral options like Rybelsus lag behind injectables.[8]
Sources:
[1] NEJM SURMOUNT-5 (2024)
[2] Nature Medicine real-world study (2024)
[3] NEJM SURMOUNT-1
[4] FDA Labels
[5] JAMA side effects meta-analysis (2024)
[6] GoodRx pricing (Oct 2024)
[7] AHA comparisons
[8] DrugPatentWatch.com GLP-1 class overview